Published eLetters
Guidelines
As a forum for professional feedback, submissions of letters are open to all. You do not need to be a subscriber. To avoid redundancy, we urge you to read other people's letters before submitting your own. Name, current appointment, place of work, and email address are required to send a letter, and will be published with your review. We also require that you declare any competing financial interests. Unprofessional submissions will not be considered or responded to.
Jump to comment:
- Page navigation anchor for Targeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disordersTargeting Peroxynitrite as a novel hypothesized treatment for autism spectrum disordersShow More
Maezawa et al. reported that a possible therapeutic target for Rett syndrome is microglia glutamate synthesis or release, confirm that NMDA glutamate receptor antagonist may improve autism spectrum disorders (ASD) (Niederhofer 2007), and suggest that glutaminase inhibitors or gap junction hemichannel blockers may be appropriate therapeutic targets.
Another potential therapeutic target is peroxynitrite. Agonists of NMDA...
Competing Interests: None declared.